Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518160) titled 'JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study' on April 1.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Condition:
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Intervention:
Drug: JS212 for Injection+JS111 capsules (AP-L1898)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 23, 2026
Ta...